Arbutus Biopharma Corp Total Liabilities and Equity
Arbutus Biopharma Corp (ABUS) had Total Liabilities and Equity of $274.02 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet
us-gaap:LiabilitiesAndStockholdersEquity · last filed 2026-08-12
- 2013-12-31: Liabilities and Equity 71.72M CAD.
- 2012-12-31: Liabilities and Equity 52.60M CAD; Liabilities and Equity as first filed 52.33M CAD.
- 2011-12-31: Liabilities and Equity 13.99M CAD.
- 2010-12-31: Liabilities and Equity 21.02M CAD.
CAD
| Period end | Liabilities and Equity | Liabilities and Equity as first filed |
|---|---|---|
| 2013-12-31 | 71.72M CAD 10-K · filed 2014-03-28 | |
| 2012-12-31 | 52.60M CAD 10-K · filed 2014-03-28 | 52.33M CAD 20-F · filed 2013-03-27 |
| 2011-12-31 | 13.99M CAD 20-F · filed 2013-03-27 | |
| 2010-12-31 | 21.02M CAD 20-F · filed 2012-03-27 |
USD
| Period end | Liabilities and Equity |
|---|---|
| 2026-06-30 | $274.02M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $277.16M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $94.62M 10-Q · filed 2026-08-12 |
| 2025-09-30 | $97.71M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $103.27M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $117.01M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $131.71M 10-K · filed 2026-03-23 |
| 2024-09-30 | $140.44M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $160.04M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $150.29M 10-Q · filed 2024-05-02 |
| 2023-12-31 | $144.40M 10-K · filed 2025-03-27 |
| 2023-09-30 | $158.64M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $176.82M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $191.22M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $195.42M 10-K · filed 2024-03-05 |
| 2022-09-30 | $203.80M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $215.84M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $236.88M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $204.49M 10-K · filed 2023-03-02 |
| 2021-09-30 | $165.60M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $135.38M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $146.24M 10-Q · filed 2021-05-05 |
| 2020-12-31 | $137.08M 10-K · filed 2022-03-03 |
| 2020-09-30 | $131.10M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $97.63M 10-Q · filed 2020-08-07 |
| 2020-03-31 | $102.61M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $105.53M 10-K · filed 2021-03-04 |
| 2019-09-30 | $117.28M 10-Q · filed 2019-11-06 |
| 2019-06-30 | $192.57M 10-Q · filed 2019-08-05 |
| 2019-03-31 | $209.22M 10-Q · filed 2019-05-06 |
| 2018-12-31 | $227.91M 10-K · filed 2020-03-05 |
| 2018-09-30 | $245.42M 10-Q · filed 2018-11-07 |
| 2018-06-30 | $277.01M 10-Q · filed 2018-08-03 |
| 2018-03-31 | $270.03M 10-Q · filed 2018-05-04 |
| 2017-12-31 | $237.16M 10-K · filed 2019-03-07 |
| 2017-09-30 | $239.84M 10-Q · filed 2017-11-02 |
| 2017-06-30 | $255.07M 10-Q · filed 2017-08-03 |
| 2017-03-31 | $268.14M 10-Q · filed 2017-05-04 |
| 2016-12-31 | $275.92M 10-K · filed 2018-03-16 |
| 2016-09-30 | $514.73M 10-Q · filed 2016-11-03 |
| 2016-06-30 | $530.86M 10-Q · filed 2016-08-04 |
| 2016-03-31 | $703.25M 10-Q · filed 2016-05-04 |
| 2015-12-31 | $712.29M 10-K · filed 2017-03-22 |
| 2015-09-30 | $722.63M 10-Q · filed 2015-11-05 |
| 2015-06-30 | $773.82M 10-Q · filed 2015-08-07 |
| 2015-03-31 | $787.06M 10-Q · filed 2015-05-06 |
| 2014-12-31 | $118.18M 10-K · filed 2016-03-09 |
| 2014-09-30 | $125.06M 10-Q · filed 2014-11-07 |
| 2014-06-30 | $132.07M 10-Q · filed 2014-08-14 |
| 2014-03-31 | $138.52M 10-Q · filed 2014-05-14 |
| 2013-12-31 | $71.72M 10-K · filed 2015-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |